^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5)

    i
    Other names: Cytochrome P450 Family 3 Subfamily A Member 5, Cytochrome P450, Subfamily IIIA (Niphedipine Oxidase), Polypeptide 5, Cytochrome P450, Family 3, Subfamily A, Polypeptide 5, Cytochrome P450-PCN3, Cytochrome P450 3A5, CYPIIIA5, P450PCN3, CP35, PCN3, Flavoprotein-Linked Monooxygenase, Aryl Hydrocarbon Hydroxylase, Microsomal Monooxygenase, Xenobiotic Monooxygenase, Cytochrome P450 HLp2, CYP3A5
    1m
    Title: Impact of CYP3A5*3 genetic polymorphism on breast cancer risk: Evidence from Bangladesh. (PubMed, Curr Probl Cancer)
    Our findings suggest that the CYP3A5*3 polymorphism is significantly associated with an elevated risk of breast cancer in Bangladeshi population.
    Journal
    |
    CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5)
    2ms
    De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients (clinicaltrials.gov)
    P3, N=60, Active, not recruiting, Virginia Commonwealth University | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2025 --> Mar 2026
    Enrollment closed • Trial primary completion date
    |
    CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5)
    |
    Valcyte (valganciclovir)
    2ms
    Interindividual variability in imatinib metabolism in human liver microsomes and primary human hepatocytes: Impact of CYP2C8 and CYP3A phenotypes. (PubMed, Drug Metab Dispos)
    Our findings provide evidence that CYP2C8 phenotypic measures (enzyme activity and protein concentration) are effective in predicting imatinib metabolism in vitro in primary human hepatocytes. Future studies are warranted to examine how preemptive testing of P450 parameters, such as phenotypes and genotypes, in patients before drug administration could aid in therapy optimization and reduction of drug toxicities.
    Journal
    |
    CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5)
    |
    imatinib
    2ms
    Impacts of polymorphisms in drug-metabolizing enzyme and transporter genes on irinotecan toxicity and efficacy in Thai colorectal cancer patients. (PubMed, PLoS One)
    UGT1A1*6 and ABCC2 -24C > T variants emerge as potential predictors of irinotecan-induced neutropenia, while UGT1A1*6 and SLCO1B1 521T > C may serve as markers of prolonged PFS in Thai patients. Validation through larger prospective studies is essential to confirm and refine these genetic associations.
    Retrospective data • Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • ABCC2 (ATP Binding Cassette Subfamily C Member 2) • ABCC5 (ATP Binding Cassette Subfamily C Member 5) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5) • ABCG1 (ATP Binding Cassette Subfamily G Member 1)
    |
    irinotecan
    3ms
    The Impact of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Cyclosporine Concentration in Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation. (PubMed, Clin Transplant)
    Cyclosporine A (CsA) is used as graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (HSCT)...In conclusion, patients carrying rs776746 or rs2740574 achieved higher CsA trough levels and may require lower initial dosing. Future research should assess whether genotype-guided CsA dosing improves achieving therapeutic levels and reduces early toxicity or suboptimal immunosuppression post-HSCT.
    Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5)
    |
    cyclosporin A microemulsion
    3ms
    Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer. (PubMed, Clin Transl Sci)
    Genetic variation in SULT2A1 may be useful to inform personalized dosing of abiraterone. ClinicalTrials.gov Identifier: NCT01949337.
    Clinical • P3 data • Journal
    |
    CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5) • SLCO2B1 (Solute Carrier Organic Anion Transporter Family Member 2B1) • UGT1A4 (UDP Glucuronosyltransferase Family 1 Member A4)
    |
    Xtandi (enzalutamide) • abiraterone acetate
    3ms
    Epigenetically inhibiting CYP3A5 modulates the migration and invasion of esophageal squamous cell carcinoma. (PubMed, Drug Metab Dispos)
    Intriguingly, administration of the histone deacetylase inhibitor trichostatin A resulted in the upregulation of CYP3A5 expression...Because ESCC develops, CYP3A5 suppression promotes tumor metastasis and invasion. CYP3A5 is a potential biomarker and therapeutic target for ESCC.
    Journal
    |
    CREBBP (CREB binding protein) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5) • HDAC4 (Histone Deacetylase 4)
    |
    trichostatin A (VTR-297)
    3ms
    Towards Personalized Chemotherapy in Gastrointestinal Cancers: Prospective Analysis of Pharmacogenetic Variants in a Russian Cohort. (PubMed, Genes (Basel))
    Several clinically relevant variants were identified: DPYD rs2297595 occurred more frequently than in European cohorts, and UGT1A1 rs8175347 was observed at a higher prevalence, underscoring the potential risk of irinotecan-related neutropenia and diarrhea... This study provides the first comprehensive description of pharmacogenetic polymorphisms in a Russian cohort of patients with gastrointestinal cancers. Our findings confirm the clinical importance of DPYD and UGT1A1 testing and highlight additional variants of potential interest.
    Observational data • Journal
    |
    ERCC1 (Excision repair cross-complementation group 1) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • GSTP1 (Glutathione S-transferase pi 1) • TYMS (Thymidylate Synthetase) • MTHFR (Methylenetetrahydrofolate Reductase) • XPC (XPC Complex Subunit, DNA Damage Recognition And Repair Factor) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5) • DPYD (Dihydropyrimidine Dehydrogenase) • SLC31A1 (Solute Carrier Family 31 Member 1)
    |
    irinotecan
    3ms
    Genetic landscape and therapeutic evolution of cyclophosphamide: spotlight on breast cancer. (PubMed, J Chemother)
    Null variants in GSTM1 and GSTT1 are linked to increased drug toxicity due to impaired detoxification. DNA repair gene variants, such as XRCC1 Arg399Gln and ERCC2 Lys751Gln, influence treatment response and risk of side effects.
    Review • Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ERCC1 (Excision repair cross-complementation group 1) • ERCC2 (Excision repair cross-complementation group 2) • GSTP1 (Glutathione S-transferase pi 1) • ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1) • CYP2C9 (Cytochrome P450 Family 2 Subfamily C Member 9) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5) • GSTM1 (Glutathione S-transferase mu 1) • XRCC1 (X-Ray Repair Cross Complementing 1) • GSTT1 (Glutathione S-transferase theta 1)
    |
    cyclophosphamide
    4ms
    Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients. (PubMed, Cancer Metastasis Rev)
    Hence, further comprehensive research is essential to examine these genetic variants across different ethnic groups, monitor the drug-drug interactions, and study the phenoconversion to draw definitive conclusions about the pharmacokinetics of gefitinib. This could lead to the development and implementation of a genotyping-based approach for gefitinib dosage optimization in clinical settings.
    PK/PD data • Review • Journal • Adverse drug reaction
    |
    EGFR (Epidermal growth factor receptor) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • FOXO3 (Forkhead box O3) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5) • UGT1A7 (UDP Glucuronosyltransferase Family 1 Member A7)
    |
    gefitinib
    4ms
    Novel molecular biomarkers associated with Taxane-induced toxicities in women with breast cancer from the Brazilian Amazon. (PubMed, Clin Transl Oncol)
    These findings represent a unique contribution to the field, potentially enabling more precise chemotherapy selection, particularly for populations such as Amazonian women.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • NOTCH1 (Notch 1) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ERCC1 (Excision repair cross-complementation group 1) • ERCC2 (Excision repair cross-complementation group 2) • RAD51 (RAD51 Homolog A) • MTHFR (Methylenetetrahydrofolate Reductase) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5) • XRCC1 (X-Ray Repair Cross Complementing 1) • CYP1A1 (Cytochrome P450 Family 1 Subfamily A Member 1) • CYP1B1 (Cytochrome P450 Family 1 Subfamily B Member 1) • SOD2 (Superoxide Dismutase 2)
    |
    paclitaxel • docetaxel